(18) A Scoping Review of Drug Exposures and The Development of Parkinson's Disease

Sunday, August 28, 2022

8:00 AM – 1:45 PM CEST

Location: Hall C

Publication Number: 1063

Presenting Author(s)

Takahiro Itaya
– University College London, London, United Kingdom

Co-Author(s)

Brendan Hallam
– Research Department of Primary Care and Population Health, University College London, United Kingdom
Mine Orlu
– UCL School of Pharmacy, University College London, United Kingdom
Anette Schrag
– Department of Clinical and Movement Neurosciences, University College London, United Kingdom
Irene Petersen
– Research Department of Primary Care and Population Health, University College London, United Kingdom
Kate Walters
– Research Department of Primary Care and Population Health, University College London, United Kingdom

Background: Parkinson's disease (PD) is a neurodegenerative disorder with no known cause and several postulated mechanisms. A range of studies have explored associations of certain drugs and risk of PD.

Objectives: Scoping review to identify and summarise the drugs associated with risk of developing PD.

Methods: We searched three literature databases (Medline, Embase, and Web of Science) identifying original research articles published until September 30, 2021. To summarise the drug category, we used the British National Formulary.

Results: We identified 7,404 papers for initial screening and included 102 eligible articles studied 187 drugs, mostly cohort and case-control studies, in this review. Most studies that examined "2.4 Beta-adrenoceptor blocking drugs" (7/12 studies) showed the association with increased PD risk. Many studies that examined "2.12 Lipid-regulating drugs" (8/18 studies) and "6.1 Drugs used in diabetes" (9/22 studies) showed the association with decreased risk. Whereas studies of "6.4 Sex Hormones" was conflicting results with increased and decreased risk (5 studies showed an increased risk; 4 studies showed a decreased risk; 11 studies showed no association), and most studies of "10.1 Drugs used in rheumatic diseases and gout", especially NSAIDs, showed no association (2 study showed an increased risk; 5 studies showed a decreased risk; 20 studies including showed no association). Also, no strong evidence was reported for any of the other drug classes.

Conclusions: Few drug-classes showed a consistent association with increased (beta-adrenoceptor blocking drugs) or decreased (lipid-regulating drugs and drugs used in diabetes) risk of PD across studies. For many drugs the evidence was mixed and further research is needed.